NO20084619L - Legemiddel i form av mikropartikler - Google Patents

Legemiddel i form av mikropartikler

Info

Publication number
NO20084619L
NO20084619L NO20084619A NO20084619A NO20084619L NO 20084619 L NO20084619 L NO 20084619L NO 20084619 A NO20084619 A NO 20084619A NO 20084619 A NO20084619 A NO 20084619A NO 20084619 L NO20084619 L NO 20084619L
Authority
NO
Norway
Prior art keywords
microparticles
drug
carrier material
material particles
inhalation
Prior art date
Application number
NO20084619A
Other languages
English (en)
Norwegian (no)
Inventor
Moshe Flashner-Barak
E Itzhak Lerner
Roud Smit
Richard Van Lamoen
Erwin V Achthoven
Hans Keegstra
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20084619L publication Critical patent/NO20084619L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084619A 2006-04-03 2008-10-31 Legemiddel i form av mikropartikler NO20084619L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78919706P 2006-04-03 2006-04-03
US85477806P 2006-10-26 2006-10-26
PCT/US2007/008685 WO2007117661A2 (en) 2006-04-03 2007-04-03 Drug microparticles

Publications (1)

Publication Number Publication Date
NO20084619L true NO20084619L (no) 2008-12-16

Family

ID=38581674

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084619A NO20084619L (no) 2006-04-03 2008-10-31 Legemiddel i form av mikropartikler

Country Status (12)

Country Link
US (1) US20080057129A1 (de)
EP (1) EP2010153A2 (de)
JP (1) JP2009532489A (de)
KR (1) KR20080105174A (de)
BR (1) BRPI0709872A2 (de)
CA (1) CA2647073A1 (de)
IL (1) IL194095A0 (de)
MX (1) MX2008012794A (de)
NO (1) NO20084619L (de)
RU (1) RU2008142388A (de)
TW (1) TW200817047A (de)
WO (1) WO2007117661A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009064469A1 (en) * 2007-11-14 2009-05-22 Nektar Therapeutics Pulmonary delivery of a macrolide antibiotic
EP2296628B1 (de) 2008-05-22 2014-05-14 3M Innovative Properties Company Verfahren zur herstellung von fliessfähigen pulverförmigen arzneimittelzusammensetzungen
EP2309978B1 (de) 2008-06-26 2018-12-26 3M Innovative Properties Company Pharmazeutische trockenpulver-zusammensetzungen zur pulmonalen verabreichung und herstellungsverfahren dafür
ES2396360T3 (es) * 2008-10-09 2013-02-21 Industrial Farmaceutica Cantabria, S.A. Composición micronizada de un derivado de fenol 2,4-di sustituido
WO2010048341A1 (en) * 2008-10-22 2010-04-29 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
WO2010085780A1 (en) * 2009-01-26 2010-07-29 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG182485A1 (en) * 2010-01-15 2012-08-30 Lithera Inc Lyophilized cake formulations
EP2552414A4 (de) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd Pharmazeutische pulverzusammensetzung zur inhalation
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CA2812952A1 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EP2696888B1 (de) * 2011-04-12 2018-12-05 Moerae Matrix, Inc., Zusammensetzungen und verfahren zur prävention oder behandlung von lungenfibrose
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JP6042995B2 (ja) * 2012-11-30 2016-12-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害薬
ES2804702T3 (es) 2013-03-04 2021-02-09 Besins Healthcare Lu Sarl Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo unidas a partículas de portador
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
MX2017000855A (es) * 2014-07-18 2017-05-01 Allergan Inc Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.
FR3039990B1 (fr) 2015-08-10 2018-07-06 Rhodia Operations Procede d'encapsulation
WO2017147420A1 (en) * 2016-02-25 2017-08-31 The University Of Florida Research Foundation, Inc. Methods and compositions with vitamin d compounds for treatment of cystic fibrosis and respiratory disorders
KR20210118468A (ko) 2017-06-14 2021-09-30 크리티테크, 인크. 폐 장애의 치료 방법
WO2019135812A2 (en) * 2017-10-12 2019-07-11 Board Of Regents, The University Of Texas System Methods and devices for promoting nerve growth and regeneration
US11872240B2 (en) 2018-08-06 2024-01-16 Chander SHEKHAR Antimicrobial formulations comprising vancomycin or tobramycin
CN117241786A (zh) * 2021-03-12 2023-12-15 德克萨斯大学系统董事会 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5429566B2 (de) * 1974-09-13 1979-09-25
NL8600731A (nl) * 1986-03-21 1987-10-16 Dmv Campina Bv Verbeterde gesproeidroogde lactose en werkwijze ter bereiding ervan.
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
WO1998029141A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
EP1079807B1 (de) * 1998-05-27 2006-09-13 Euro-Celtique S.A. Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US20040043043A1 (en) * 2000-09-20 2004-03-04 Schlyter Jimmy Hirschsprung Preparation of emulsions and concentrates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
CA2461349C (en) * 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
EP2085073A1 (de) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Arzneimittelmikroteilchen
AU2003269889B2 (en) * 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
WO2004075874A1 (en) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
CA2543577A1 (en) * 2003-11-21 2005-06-16 Galderma Research & Development, S.N.C. Sprayable composition for the administration of vitamin d derivatives

Also Published As

Publication number Publication date
BRPI0709872A2 (pt) 2011-07-26
RU2008142388A (ru) 2010-05-10
KR20080105174A (ko) 2008-12-03
US20080057129A1 (en) 2008-03-06
MX2008012794A (es) 2008-10-15
WO2007117661A2 (en) 2007-10-18
IL194095A0 (en) 2009-08-03
JP2009532489A (ja) 2009-09-10
CA2647073A1 (en) 2007-10-18
EP2010153A2 (de) 2009-01-07
WO2007117661A3 (en) 2008-01-17
TW200817047A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
NO20084619L (no) Legemiddel i form av mikropartikler
WO2010047765A8 (en) Nanostructures for drug delivery
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
NO20071751L (no) Fremgangsmater og kit for levering av legemidler ved nebulisering
WO2007070851A3 (en) Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
EA200800160A1 (ru) Композиты восстановленной ионной жидкостью целлюлозы в качестве матриц твёрдых подложек
CY1106269T1 (el) Σωματιδια σκονης με λεια επιφανεια για χρηση σε θepαπεια με εισπνοη
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
BR112016026699A8 (pt) uso de amicacina ou de um sal farmaceuticamente aceitável desta
TW200640908A (en) Chemical compounds
BRPI0809011A8 (pt) composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
MY141025A (en) Dose forms
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
NO20051414L (no) Fremgangsmate for fremstilling av torrpulverinhaleringssammensetninger
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2009032034A3 (en) Stabilized picoplatin dosage form
MX2013013503A (es) Composiciones de vancomicina en polvo seco y metodos asociados.
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
BR112014008609A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, método para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
NO20082396L (no) Fremgangsmater for behandling av mave-tarmkanalinfeksjoner med tigecyclin
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application